Statin therapy on glycaemic control in type 2 diabetes: a meta-analysis

Bibliography

• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
   PubMed Web of Science ®Google Scholar
• Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-25
   PubMed Web of Science ®Google Scholar
• Armitage J. The safety of statins in clinical practice. Lancet 2007;370:1781-90
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96
   PubMed Web of Science ®Google Scholar
• Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006;29:1220-6
   PubMed Web of Science ®Google Scholar
• Sever PS, Poulter NR, Dahlof B, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care 2005;28:1151-7
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42
   PubMed Web of Science ®Google Scholar
• Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011;305:2556-64
   PubMed Web of Science ®Google Scholar
• Waters DD, Ho JE, DeMicco DA, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol 2011;57:1535-45
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm 2012
   Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12
   PubMedGoogle Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60
   PubMed Web of Science ®Google Scholar
• Abe M, Maruyama N, Okada K, et al. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. J Atheroscler Thromb 2011;18:1018-28
   PubMed Web of Science ®Google Scholar
• Jinnouchi Y, Yamagishi S, Takeuchi M, et al. Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin Exp Med 2006;6:191-3
   PubMed Web of Science ®Google Scholar
• M Zafar Iqbal H, Rashida Q, M Yakoob A, et al. Effect of simvastatin on insulin sensitivity in type 2 diabetic subjects. Pak J Med Sci 2007;23:755-9
   Google Scholar
• Gupta A, Gupta V, Thapar S, et al. Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am J Ophthalmol 2004;137:675-82
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34
   PubMed Web of Science ®Google Scholar
• Scharnagl H, Stojakovic T, Winkler K, et al. The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2007;115:372-5
   PubMed Web of Science ®Google Scholar
• Balletshofer BM, Goebbel S, Rittig K, et al. Intense cholesterol lowering therapy with a HMG-CoA reductase inhibitor does not improve nitric oxide dependent endothelial function in type-2-diabetes – a multicenter, randomised, double-blind, three-arm placebo-controlled clinical trial. Exp Clin Endocrinol Diabetes 2005;113:324-30
   PubMed Web of Science ®Google Scholar
• Dalla Nora E, Passaro A, Zamboni PF, et al. Atorvastatin improves metabolic control and endothelial function in type 2 diabetic patients: a placebo-controlled study. J Endocrinol Invest 2003;26:73-8
   PubMed Web of Science ®Google Scholar
• Farrer M, Winocour PH, Evans K, et al. Simvastatin in non-insulin-dependent diabetes mellitus: effect on serum lipids, lipoproteins and haemostatic measures. Diabetes Res Clin Pract 1994;23:111-19
   PubMed Web of Science ®Google Scholar
• Heljic B, Velija-Asimi Z, Kulic M. The statins in prevention of coronary heart diseases in type 2 diabetics. Bosn J Basic Med Sci 2009;9:71-6
   PubMed Web of Science ®Google Scholar
• Tanaka A, Yamada N, Saito Y, et al. A double-blind trial on the effects of atorvastatin on glycemic control in Japanese diabetic patients with hypercholesterolemia. Clin Chim Acta 2001;312:41-7
   PubMed Web of Science ®Google Scholar
• Freed MI, Ratner R, Marcovina SM, et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002;90:947-52
   PubMed Web of Science ®Google Scholar
• Szendroedi J, Anderwald C, Krssak M, et al. Effects of high-dose simvastatin therapy on glucose metabolism and ectopic lipid deposition in nonobese type 2 diabetic patients. Diabetes Care 2009;32:209-14
   PubMed Web of Science ®Google Scholar
• Krysiak R, Gdula-Dymek A, Okopien B. Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia. Am J Cardiol 2011;107:1010-18. e1
   PubMed Web of Science ®Google Scholar
• Nakamura T, Ushiyama C, Hirokawa K, et al. Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am J Nephrol 2001;21:449-54
   PubMed Web of Science ®Google Scholar
• Nielsen S, Schmitz O, Moller N, et al. Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1993;36:1079-86
   PubMed Web of Science ®Google Scholar
• Lam KS, Cheng IK, Janus ED, et al. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995;38:604-9
   PubMed Web of Science ®Google Scholar
• Diabetes Atorvastin Lipid Intervention (DALI) Study Group. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 2001;24:1335-41
   PubMedGoogle Scholar
• Usharani P, Mateen AA, Naidu MU, et al. Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study. Drugs R D 2008;9:243-50
   PubMed Web of Science ®Google Scholar
• Neil HA, Ceglarek U, Thiery J, et al. Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: a randomised placebo controlled factorial trial. Atherosclerosis 2010;213:512-17
   PubMed Web of Science ®Google Scholar
• Sheu WH, Jeng CY, Lee WJ, et al. Simvastatin treatment on postprandial hypertriglyceridemia in type 2 diabetes mellitus patients with combined hyperlipidemia. Metabolism 2001;50:355-9
   PubMed Web of Science ®Google Scholar
• Pontrelli L, Parris W, Adeli K, et al. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism 2002;51:334-42
   PubMed Web of Science ®Google Scholar
• Schneider JG, von Eynatten M, Parhofer KG, et al. Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo. Atherosclerosis 2004;175:325-31
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16
   PubMed Web of Science ®Google Scholar
• Sukhija R, Prayaga S, Marashdeh M, et al. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J Investig Med 2009;57:495-9
   PubMed Web of Science ®Google Scholar
• Moutzouri E, Liberopoulos E, Mikhailidis DP, et al. Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. Int J Clin Pract 2011;65:1141-8
   PubMed Web of Science ®Google Scholar
• Simsek S, Schalkwijk CG, Wolffenbuttel BH. Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes–the CORALL study. Diabet Med 2012;29:628-31
   PubMed Web of Science ®Google Scholar
• Yamakawa T, Takano T, Tanaka S, et al. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2008;15:269-75
   PubMedGoogle Scholar
• Baker WL, Talati R, White CM, et al. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract 2010;87:98-107
   PubMed Web of Science ®Google Scholar
• Nakata M, Nagasaka S, Kusaka I, et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006;49:1881-92
   PubMed Web of Science ®Google Scholar
• Sampson UK, Linton MF, Fazio S. Are statins diabetogenic? Curr Opin Cardiol 2011;26:342-7
   PubMed Web of Science ®Google Scholar